Evidence map›Paper›PMID 42909954›Full record

ReviewLiver cancer2026

The Impact of Frailty in Hepatocellular Carcinoma.

Rachael Jacob, Shirin Salimi, Dinuli Kamaladasa, Karen Waller, Emily He, Mark Danta, Simone I Strasser, Geoff W McCaughan, Jacob George, Ken Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rachael JacobAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Shirin SalimiAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Dinuli KamaladasaAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Karen WallerFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Emily HeFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Mark DantaDepartment of Gastroenterology and Hepatology, St Vincent's Hospital, Sydney, NSW, Australia.
Simone I StrasserAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0001-6374-1525
Geoff W McCaughanFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Jacob GeorgeFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Ken LiuAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) represents an increasing global health challenge, associated with poor prognosis and an epidemiological shift towards an aging and comorbid population. Frailty is a multidimensional syndrome of reduced physiological reserve. It is recognized as a robust predictor of clinical outcomes in chronic liver disease and some cancers but remains underexplored in HCC. Summary: This narrative review synthesizes current evidence on the clinical significance of frailty in HCC, focusing on its impact on outcomes, evidence for targeted interventions, and potential role in clinical decision-making. Frailty is associated with adverse outcomes in HCC, including increased healthcare utilization, reduced treatment tolerance, and decreased survival. However, heterogeneity in frailty assessment methods and limited prospective data preclude its clinical application. Early evidence suggests that structured exercise programs are safe, feasible, and may improve frailty measures, although larger prospective studies are required to determine whether these translate into meaningful clinical benefits. Key Messages: Frailty is an emerging prognostic marker and may inform supportive care in HCC. Standardized assessment and interventional trials are needed to support routine integration of frailty for more personalized HCC management.

Indexed as

FrailtyHepatocellular carcinomaInterventionSurvival

Identifiers

PMID42909954
PMCPMC13685679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.